Tags

Type your tag names separated by a space and hit enter

Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Anticancer Res. 2004 May-Jun; 24(3b):2061-8.AR

Abstract

BACKGROUND

Several factors are currently employed for prognosis assessment and treatment determination in breast cancer. An array of molecular parameters, such as p53, Her2-neu (c-erbB 2) and Cathepsin-D, are also examined to improve clinical patient management. We have conducted a statistically powerful study of the prognostic value of conventional factors and of the investigational factors p53, Her2-neu and Cathepsin-D in patients with invasive breast carcinoma, in order to compare their significance. Our analysis was extended to determine the associations of p53 and Her2-neu with risk of death and relapse among patients with and without lymph node metastases.

MATERIALS AND METHODS

In a set of 125 primary breast tumors, p53 and Her2-neu expression were immunohistochemically evaluated. Cathepsin-D, estrogen and progesterone receptor concentrations were determined in cytosols by a standard immunoradiometric assay.

RESULTS

Over a mean of 62 months, 49 patients (39%) had a relapse and 29 patients (23%) died. Overexpression of p53, Her2-neu and Cathepsin-D was observed in 31%, 46% and 88% of cases, respectively. Overall survival was associated with histology (hazard ratio 0.04, 95% confidence interval: 0.01, 0.49 for lobular tumors) and stage (hazard ratio 5.94, 95% confidence interval: 1.30, 27.15 for stage III samples). Disease-free survival was also related to histology (hazard ratio 0.23, 95% confidence interval: 0.08, 0.73 for lobular tumors) and stage (hazard ratio 4.27, 95% confidence interval: 1.36, 13.36 for stage III tumors). Patients with both negative nodal status and Her2-neu overexpression tended to display an elevated risk of death.

CONCLUSION

Our results support the prognostic power of tumor histology and stage and emphasize the need for further studies on the prognostic impact of p53. Her2-neu and Cathepsin-D in breast cancer. Additionally, our analysis indicates that deregulation of Her2-neu might characterize a subgroup of node-negative patients with poor prognosis who could benefit from an aggressive adjuvant therapy.

Authors+Show Affiliations

Department of Surgery, St Savvas Hospital, Athens, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15274401

Citation

Korkolis, D P., et al. "Tumor Histology and Stage but Not P53, Her2-neu or cathepsin-D Expression Are Independent Prognostic Factors in Breast Cancer Patients." Anticancer Research, vol. 24, no. 3b, 2004, pp. 2061-8.
Korkolis DP, Tsoli E, Fouskakis D, et al. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Res. 2004;24(3b):2061-8.
Korkolis, D. P., Tsoli, E., Fouskakis, D., Yiotis, J., Koullias, G. J., Giannopoulos, D., Papalambros, E., Nikiteas, N. I., Spiliopoulou, C. A., Patsouris, E., Asimacopoulos, P., & Gorgoulis, V. G. (2004). Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Research, 24(3b), 2061-8.
Korkolis DP, et al. Tumor Histology and Stage but Not P53, Her2-neu or cathepsin-D Expression Are Independent Prognostic Factors in Breast Cancer Patients. Anticancer Res. 2004 May-Jun;24(3b):2061-8. PubMed PMID: 15274401.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. AU - Korkolis,D P, AU - Tsoli,E, AU - Fouskakis,D, AU - Yiotis,J, AU - Koullias,G J, AU - Giannopoulos,D, AU - Papalambros,E, AU - Nikiteas,N I, AU - Spiliopoulou,C A, AU - Patsouris,E, AU - Asimacopoulos,P, AU - Gorgoulis,V G, PY - 2004/7/28/pubmed PY - 2004/9/10/medline PY - 2004/7/28/entrez SP - 2061 EP - 8 JF - Anticancer research JO - Anticancer Res VL - 24 IS - 3b N2 - BACKGROUND: Several factors are currently employed for prognosis assessment and treatment determination in breast cancer. An array of molecular parameters, such as p53, Her2-neu (c-erbB 2) and Cathepsin-D, are also examined to improve clinical patient management. We have conducted a statistically powerful study of the prognostic value of conventional factors and of the investigational factors p53, Her2-neu and Cathepsin-D in patients with invasive breast carcinoma, in order to compare their significance. Our analysis was extended to determine the associations of p53 and Her2-neu with risk of death and relapse among patients with and without lymph node metastases. MATERIALS AND METHODS: In a set of 125 primary breast tumors, p53 and Her2-neu expression were immunohistochemically evaluated. Cathepsin-D, estrogen and progesterone receptor concentrations were determined in cytosols by a standard immunoradiometric assay. RESULTS: Over a mean of 62 months, 49 patients (39%) had a relapse and 29 patients (23%) died. Overexpression of p53, Her2-neu and Cathepsin-D was observed in 31%, 46% and 88% of cases, respectively. Overall survival was associated with histology (hazard ratio 0.04, 95% confidence interval: 0.01, 0.49 for lobular tumors) and stage (hazard ratio 5.94, 95% confidence interval: 1.30, 27.15 for stage III samples). Disease-free survival was also related to histology (hazard ratio 0.23, 95% confidence interval: 0.08, 0.73 for lobular tumors) and stage (hazard ratio 4.27, 95% confidence interval: 1.36, 13.36 for stage III tumors). Patients with both negative nodal status and Her2-neu overexpression tended to display an elevated risk of death. CONCLUSION: Our results support the prognostic power of tumor histology and stage and emphasize the need for further studies on the prognostic impact of p53. Her2-neu and Cathepsin-D in breast cancer. Additionally, our analysis indicates that deregulation of Her2-neu might characterize a subgroup of node-negative patients with poor prognosis who could benefit from an aggressive adjuvant therapy. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/15274401/Tumor_histology_and_stage_but_not_p53_Her2_neu_or_cathepsin_D_expression_are_independent_prognostic_factors_in_breast_cancer_patients_ L2 - http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=15274401 DB - PRIME DP - Unbound Medicine ER -